Newsroom

iRhythm Technologies has partnered with BioIntelliSense to enhance its cardiac monitoring platform with advanced sensor technology. This collaboration aims to improve continuous patient monitoring and expand iRhythm's reach into areas like sleep apnea, boosting patient outcomes and healthcare efficiency.

Fitzsimons Innovation Community and CU Innovations partner to advance healthcare by connecting startups with the University of Colorado Anschutz Medical Campus. Dr. Gali Baler emphasizes engagement between companies and campus, in addition to programs like SPARK and the Startup Foundry, which provide funding, resources, and mentorship, driving impactful innovations in patient care.

Q32 Bio’s innovative approach to targeting the complement system could revolutionize treatments for various diseases. If successful, their research may provide a “skeleton key” to address a wide array of health conditions.

CU Innovations proudly unveils its newly redesigned website featuring the Sophia Inventor Portal. As part of our ongoing commitment to providing innovators with the best experience, we have enhanced our online platform to improve usability, navigation and save you time!

Steve VanNurden, MBA, wants CU Innovations to be known for one thing: how well it helps translate ideas from idealism into action. It’s a statement borrowed from Charlie Mayo, a founder of Mayo Clinic, where VanNurden began his career in innovation 34 years ago.

Last year CU Innovations’ activities resulted in 145 invention disclosures, 189 patents filed, 41 licensing deals, $375MM of startup financing, and $35MM of gross revenue to the University of Colorado campus having a significant economic impact both in Colorado and nationwide.

Becoming a successful innovator and entrepreneur can be a daunting and difficult process, which is why the University of Colorado Anschutz Medical Campus has developed extensive resources to help its researchers find success in developing novel ways to help others. With hopes of inspiring faculty and offering tangible advice, the CU Department of Medicine highlighted these resources during its latest Research Achievement Highlights (REACH) forum through presentations by two experts: V. Michael Holers, MD, and Gali Baler, PhD.

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the completion of its merger with Homology Medicines, Inc. ("Homology").